By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.
What Root to Rx Is
Free, every week, no sponsor.
Wednesday, Plain Talk. Each issue now opens in The Root Room, where you watch a real health claim try to work on somebody. Then we take it apart in plain language, with the receipts at the foot of it.
Tuesday, The Open Site File. What the job actually looks like from inside a clinical trial site. If you have ever thought about moving into clinical research coordinating, start there.
Sunday, The Roots, on LinkedIn and Substack. A weekly letter for the people who get asked, the ones whose family treats them as the medical desk.
The Room Where the Target Gets Picked
Every spring, one room picks the target for fall, as Rooty the Researcher and Sam the Skeptic watch on.
“Is this where they approve it?” Sam the Skeptic asks.
The room is quieter than he expected. Long tables, microphones, a screen at the front covered in a map of colored dots. Each dot is a version of the virus somebody found in a lab sample.
“This is where they pick what it’s aimed at,” Rooty says, nodding toward the adviser at the screen. “Every spring, the FDA’s vaccine advisers look at which versions are spreading and choose one target for the fall. This year, on May 28, they chose one called XFG.”
“And then they run a whole new trial?”
“No. The vaccine’s design already went through large trials years ago. The update gets judged mostly on lab and manufacturing data, with more studies after approval. Flu vaccines have been updated the same way for decades.”
Rooty the Researcher taps the table. “Remember what this room does. It answers these questions: is it safe and effective, and for whom? It doesn’t answer who should actually get it. That’s a different room.”
“Where’s that one?”
“Down the hall. As of October 10, 2026, it hasn’t met for this season.”
Two of our helpers are sitting in with you, as always. Sam the Skeptic, who asks how do we know and never lets anyone skip the question, including us. And Rooty the Researcher, who brings the receipts. This week they sat in on a room most people never see.
Ray’s Living Room, That Night
The news said one thing. The label says another. Both are half true.
Ray has the evening news on when Maya stops by with groceries.
“Well, that settles it,” he says, pointing the remote at the screen. “Even the CDC won’t recommend it anymore. If it were safe, they’d say so.”
Maya opens her mouth. The correction is right there. She closes it again.
Sam leans toward Rooty. “She was about to win that one.”
“She was,” Rooty says. “Watch her check herself first.”
The Black Box Warning: The Missing Step
Two steps. Most headlines only show you one.
Tactic: The Missing Step.
Tool: take something true about one step and let it stand for both.
Running it: “It’s approved, so everyone should get it.” Also “nobody recommends it, so it must not be safe.”
Nobody has to say anything false for this one to work. Both halves can be true at the same time. The trick is folding two steps into one.
Move 1. Report one step. The approval, or the missing recommendation.
Put it this way. A driver’s license says you’re allowed to drive. It doesn’t say you should drive tonight in a snowstorm.
Move 2. Let that one step stand for the whole process.
Put it this way. A restaurant that passed its health inspection hasn’t been recommended by anyone. And a restaurant with no reviews yet didn’t fail its inspection.
Move 3. Skip the question that would break it: which step, and for whom?
Put it this way. Ask which room made the call, and who it was made for.
She Checks Herself First
Here’s what’s going on in Maya’s head, and it’s the OPEN card, start to finish.
Own your intention. Is she here to help her dad, or to beat him?
Picture his story. His friend Gene spent a week in the hospital with COVID last winter, and Ray drove Gene’s wife back and forth every day. He isn’t against the vaccine. He’s confused, and a little scared. Explore before you explain, and then name something real you share.
She sets the groceries down and sits next to him on the couch, not across from him. “We both want you at the grandkids’ Christmas. So I’m curious. Where’d you hear that?”
“Right there. Something about a committee that didn’t vote.”
“What would make you feel sure, one way or the other?”
Ray thinks about it. “If Dr. Okafor told me.”
They Look Together
“Want to see what it actually says?” Maya pulls up the label on her phone and holds it where they can both read it. Approved for adults 65 and older, and for younger people with certain conditions that raise their risk.
“I’m 72,” Ray says.
“So you’re on the label. The news was talking about the other step.”
Rooty turns to Sam. “That’s PAUSE. She paused. She asked the source. She found his bar, and it’s his doctor, which is a good bar. Then they searched together, instead of her reading him results like a prosecutor.”
“Did she change his mind?”
“She didn’t try to. Watch.”
What Ray Decides
Ray takes the Medical History Log off the fridge, the one they started last week, and writes at the bottom: ask Dr. Okafor about the fall vaccine.
He doesn’t decide anything tonight. He doesn’t have to. The decision just moved to the person who can see his whole list. That isn’t a win for Maya and it isn’t a loss for Ray. It’s the conversation working.
The move to keep
Approved and recommended are two different steps, in two different rooms. Ask which one they mean, and who it’s meant for. And before you ask anything, check whether you’re there to help or there to win.
That’s the scene. Now the rulebook behind it.
Plain Talk is Root to Rx's weekly teardown of something in the news: what happened, what the evidence says, and the one question that beats the confusion.
This is Small Doses, No. 3 of 12. Each week, one viral health claim, taken apart a small dose at a time. This week, the fall COVID vaccine.
The 30 second version
This fall's updated COVID vaccines are approved. The FDA signed off on them in late summer.
But approval is only step one. Step two is a recommendation from the CDC's vaccine advisers about who should get them, and for this season that step hasn't happened yet.
The question to carry: approved for whom, and recommended by whom?
In the news
The FDA approved updated 2026 to 2027 COVID vaccines from Pfizer and BioNTech, Moderna and Novavax, all aimed at a variant called XFG. Pharmacies started getting doses in September.
What's missing is the usual next step from the CDC's Advisory Committee on Immunization Practices, called ACIP. As of October 10, 2026, it hasn't voted on a recommendation for this season. In the meantime, several medical groups, including the American Academy of Pediatrics and the American Academy of Family Physicians, published their own.
What does FDA approval of the COVID vaccine mean?
FDA approval answers one question. Does the evidence show this product is safe and effective for a specific group of people? That group is written on the label.
This year's labels are narrower than they used to be. Pfizer's updated vaccine, for example, is approved for adults 65 and older, and for people 5 through 64 who have at least one condition that raises their risk of severe COVID.
How is the updated COVID vaccine approved so fast?
This is the part that sounds suspicious and isn’t, and the Root Room scene above already walked into the room where it starts.
Same lenses, new strength. Same design, this year’s virus.
Think about someone’s glasses. When their prescription changes, they don’t get a new kind of glasses. That person gets the same lenses at a new strength. Nobody runs new safety trials on the lens just because their eyes changed a little since last year.
The fall vaccine works the same way. The design was already tested in large trials. Every spring, FDA advisers check which versions of the virus are spreading and pick a target, a bit like an eye exam for the season. Manufacturers update the vaccine to match, and the FDA reviews that update mainly on lab and manufacturing data, with follow up studies after approval.
And like that lens prescription, the update gets signed off by someone outside the company that makes it. Flu vaccines have been updated this way every year for decades.
Who decides who should get the COVID vaccine?
A recommendation answers a different question. Of the people a vaccine is approved for, who should actually get it, and when?
In the US, that has traditionally come from ACIP and then the CDC. It matters beyond advice, because insurance coverage for many plans is tied to ACIP recommendations. That's why a missing recommendation can turn into real confusion at the pharmacy counter.
The most recent official CDC recommendation still dates from September 2025. It says COVID vaccination should be an individual decision made with a health care provider, for everyone 6 months and older, and that for people under 65, the benefit is most favorable for those at higher risk of severe COVID.
The one question that beats it
Approved for whom, and recommended by whom?
When you hear "the vaccine is approved" or "nobody recommends it anymore," both can be partly true at the same time. Ask which step the person means, and which group of people they're talking about.
It's a pocket version of Q6 from our Skeptic's Toolkit: am I seeing the full picture, or only part of it? Here's the full set.
Copy this
For the next time someone says "it's approved, so everyone should get it," or "if it were safe, the CDC would recommend it":
"Those are two different steps. The FDA approves a vaccine for specific groups of people. Then the CDC's advisers recommend who should actually get it. This fall the first step is done and the second one hasn't happened yet. So the real question is: approved for whom, and recommended by whom?"
What this means for you
If you're deciding about this fall's vaccine, the label tells you who it's approved for, and your doctor or pharmacist can walk you through your own risk. That conversation goes faster when your conditions are written down, and our free Medical History Log puts them on one page. If cost is a question, call your insurance plan before you go.
The Bridge
Clinical trials are a door, and most people walk right past it. In a 2020 national survey, more than 90 percent of U.S. adults said they knew little or nothing about clinical trials. That's not your fault. Nobody put up a sign. It's also why news like this fall's vaccine update gets confusing fast. So I'm putting a sign up: trials are listed publicly, and you can browse them on our registries page. Looking commits you to nothing. It just means the next time a trial comes up, you'll know the word.
Clinical Research is a bridge from discovery all the way to people’s lives. From basic research discoveries of drug candidates and targets, to clinical trials and drug approvals, the entire bridge can take decades.
Where this fall's COVID vaccine sits: We know, for the groups on the label. The original design crossed the bridge in large trials, and each yearly update is reviewed mostly on lab and manufacturing data, the way flu vaccines are. The step still pending, the recommendation, happens after the bridge, not on it.
-Justin
The Wall of Sams
Reply to this email or leave a comment on the newsletter: what have you heard at the pharmacy or from family about this fall's vaccines? What was most confusing?
Send this to one person
The parent trying to figure out what the pediatrician will say this year. The grandparent who keeps asking whether it's time for another one. One person, not everyone. Use your own link below and it counts toward your Series 1 card.
Copy and send: "Clearest explanation I've seen of why this fall's COVID vaccine is approved but nobody official has said who should get it.
The Receipts
1. FDA Vaccines and Related Biological Products Advisory Committee, 2026 to 2027 COVID-19 vaccine composition, May 28, 2026. fda.gov
2. Pfizer and BioNTech, press release on FDA approval of the XFG adapted COVID-19 vaccine (COMIRNATY XFG), 2026. pfizer.com
3. FDA approvals of 2026 to 2027 formulas: Comirnaty, Spikevax, mNEXSPIKE and Nuvaxovid. [CONFIRM the FDA primary page before publishing.]
4. HHS press release, ACIP Recommends COVID-19 Immunization Based on Individual Decision-making, September 19, 2025. hhs.gov
5. 2026 to 2027 respiratory vaccine recommendations from AAP, AAFP, ACOG and IDSA, September 2026. [CONFIRM each primary link.]
6. CDC, Advisory Committee on Immunization Practices meetings and recommendations. cdc.gov/acip [CONFIRM current status.]
7. 42 U.S.C. 300gg-13, coverage of preventive services, including immunizations recommended by ACIP.
Try it yourself: see if you'd have caught this week's costume on your own.
The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type.
Got Skepticism? runs any claim through five questions, including the one from this issue: approved for whom, and recommended by whom?
Stay in the Room shows you how to disagree without a fight so that you can talk to people about these difficult topics.
The quiz and both games play in your browser at openlabelmedia.com, and I would love to see your results on social.
Work in clinical research, or want to? The Open Site File comes out every Tuesday. Get it by email:
Between issues, the free tools live on the site. The Field Guide has printable patient logs and the full Skeptic's Toolkit at roottorx.com/field-guide. If you or someone you love is looking for a trial, there's a walkthrough for finding one near you at roottorx.com/clinical-trial-registries. And if you've ever wondered why clinical research has the rules it does, Version History tells that story at roottorx.com/version-history. The tees and mugs that help support the work are at shop.roottorx.com.
For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.
Instagram: instagram.com/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | TikTok: tiktok.com/@root.to.rx | YouTube: youtube.com/@roottorx | Threads: threads.com/@roottorx | Subscribe: RootToRx.com
You are receiving this because you subscribed at roottorx.com.
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States